New jobs in the UK life sciences sector hit all-time highs in 2021 amid a record injection of government healthcare funding to position Britain as a global life sciences superpower post-Brexit, according to new research.
An annual labour market review1 by recruiters Cpl Life Sciences and data analytics firm Vacancysoft found that scientific vacancies in UK pharmaceuticals, biotech, contract research organizations and medical devices were up 58% in 2021 compared to 2020.
The most active recruiter in UK life sciences was AstraZeneca, which published over 1,000 new professional scientific vacancies last year, representing a rise of 49% year-on-year. PPD experienced the fastest growth, with a rise of 186.4% in new jobs compared to 2020.
James Chaplin, CEO of Vacancysoft, said that the UK “had a red hot life sciences labour market in 2021, following a 2020 where vacancies more or less maintained the same levels compared to 2019.” He added: “The government’s favourable conditions and incentives for the growth of the industry might see these new higher levels of new jobs maintained. No longer able to have frictionless trade with the EU, pharmaceuticals may opt to scale up in the UK instead.”
The data shows that R&D specialists are the most sought after experts, with vacancies for this function dominating the labour market, and rising by 71% year-on-year. Professional clinical vacancies, second by volume in the UK, experienced a 102% rise in relation to 2020. Hiring for PCV/drug safety experts saw the largest growth (107% year-on-year), while medical affairs vacancies were the most muted (30.7% year-on-year).
There has also been a significant hike in recruitment in CROs, the report continues, as pharma and biotech companies outsource drug development and discovery.Scientific vacancies in CROs are now broadly identical to those recorded in pharma firms, with hiring levels up 99% year-on-year. In contrast, pharma recruitment is up by only 46% compared to 2020.
The 2021 annual labour market review of the UK life sciences sector is available here.
Note
1. https://drive.google.com/file/d/1symykSY0hg5ttfbNz-HnP3HI9xe5oTJT/view
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.